Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 (Telikibart) in seasonal allergic rhinitis
NCT07154342Phase 3Recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of telikibart in seasonal allergic rhinitis (SAR), sponsored by Zhixiang Jintai. Started Aug 2025; status: recruiting.
02
Drugs
telikibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT07154342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154342.